Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
(OP:
LOBEF
)
0.0150
-0.0010 (-6.25%)
Streaming Delayed Price
Updated: 3:49 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
43,445
Open
0.0170
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0160
Today's Range
0.0102 - 0.0186
52wk Range
0.0100 - 0.0225
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Lobe Sciences Announces Creation of Wholly Owned Subsidiary, Alera Pharma, Inc.
August 15, 2024
From
Lobe Sciences Ltd
Via
Business Wire
Lobe Sciences Announces Appointment of a New Board of Directors and Executive Management Team
August 12, 2024
From
Lobe Sciences Ltd
Via
Business Wire
Performance
YTD
+7.91%
+7.91%
1 Month
-7.41%
-7.41%
3 Month
+7.14%
+7.14%
6 Month
+3.45%
+3.45%
1 Year
-6.25%
-6.25%
More News
Read More
Lobe Sciences Announces Update
June 04, 2024
From
Lobe Sciences Ltd.
Via
Business Wire
Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip!
March 01, 2023
Via
TheNewswire.com
Wesley Ramjeet to Join Lobe Sciences’ Board of Directors, Bringing Decades of Strategic Financial Expertise
June 03, 2024
From
Lobe Sciences Ltd.
Via
Business Wire
Lobe Sciences Announces Frederick D. Sancilio Ph.D. to Join Board of Directors
May 31, 2024
From
Lobe Sciences Ltd.
Via
Business Wire
Former Merck Director and Vanderbilt Vice-Chancellor, Dr. Harry Jacobson, to Join Lobe Sciences Board of Directors
May 30, 2024
From
Lobe Sciences Ltd.
Via
Business Wire
Lobe Sciences Ltd. and Clearway Global Announce Change of Control and Focus on Creating Value for Shareholders
May 21, 2024
From
Lobe Sciences Ltd.
Via
Business Wire
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
January 15, 2024
Via
Benzinga
Lobe Sciences Provides Company Review of 2023
January 08, 2024
From
Lobe Sciences Ltd.
Via
Business Wire
Lobe Sciences Provides Update on L-130 Clinical Program
December 07, 2023
From
Lobe Sciences Ltd.
Via
Business Wire
Lobe Sciences Provides Update on L-130 Oral Psilocin Compound
December 05, 2023
From
Lobe Sciences Ltd.
Via
Business Wire
Lobe Sciences, Ltd. Announces Amendment to the Acquisition of Altemia™ & Company
September 14, 2023
From
Lobe Sciences Ltd.
Via
Business Wire
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
July 04, 2023
Via
Benzinga
This Biotech Is Entering The Clinical Stage With A Psilocin Analog Targeting Cluster Headaches
June 28, 2023
Via
Benzinga
Lobe Sciences Initiates Phase 1 Clinical Trial of L-130
June 27, 2023
From
Lobe Sciences Ltd.
Via
Business Wire
Lobe Sciences Appoints Baxter Phillips III, MBA as Chief Operating Officer
June 07, 2023
From
Lobe Sciences Ltd.
Via
Business Wire
Lobe Sciences Announces Commercial Distribution Agreement With Pentec Health for US Launch of Altemia™
May 17, 2023
From
Lobe Sciences Ltd.
Via
Business Wire
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
April 24, 2023
Via
Benzinga
Psyched Business: Lobe Buys Rare Disease Treatment, Plus Healing CREI And Heally Team Up
April 20, 2023
Via
Benzinga
Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip!
February 28, 2023
Via
Benzinga
Chronic Cluster Headaches, Next Target For This Non-Hallucinogenic Psychedelic
January 27, 2023
Via
Benzinga
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry
January 26, 2023
Via
FinancialNewsMedia
Topics
Economy
Exposures
Supply Chain
Lobe Sciences, Ltd. Enters Collaborative Clinical Research Agreement with Integrative Headache Medicine of New York to Study the Effects of L-130 in the Treatment of Chronic Cluster Headache
January 26, 2023
Via
FinancialNewsMedia
Exposures
Product Safety
Lobe Sciences Ltd (LOBEF) increases its portfolio with several new chemical entities (NCEs)
January 19, 2023
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.